Autopsy report · NCT00781326

Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression

“Final cost of study medication was significantly greater than initial estimate,”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 6 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 7 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

University of Pittsburgh

Sponsor type

University, hospital or other

Conditions

Depression

Interventions

Nimodipine; Placebo

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
  “The trial was stopped early due to insufficient study drug supply and study funding constraints” (62% match in meaning)
• Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
  “due to business decision regarding the study drug.” (62% match in meaning)
• Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
  “cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug.” (62% match in meaning)
• Bevacizumab vs Dacarbazine in Metastatic Melanoma
  “Lack of financing of the study drug. Not sufficient financial support.” (61% match in meaning)
• An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants
  “Study medication was no longer available for study” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.